Showing results (541-550 of 1,794) with videos related to

Sort By:
Pageof 180
Mabs|May 4, 2021
Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLLCarlos Cuesta-Mateos, Raquel Juárez-Sánchez, Tamara Mateu-Albero, et al.
Mabs|September 7, 2021
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteinsMarlena Surowka, Wolfgang Schaefer, Christian Klein
Mabs|December 2, 2022
A novel anti-NGF PEGylated Fab' provides analgesia with lower risk of adverse effectsYukari Koya, Hirotsugu Tanaka, Eiji Yoshimi, et al.
Mabs|December 16, 2022
Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case studyDmitry Shchelokov, Oleg Demin
Mabs|December 13, 2022
Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancerJiawei Guan, Hongchuan Liu, Yan Chai, et al.
Mabs|July 20, 2021
Animal- versus in vitro-derived antibodies: avoiding the extremesAndrew R M Bradbury, Stefan Dübel, Achim Knappik, et al.
Mabs|July 6, 2021
An integrated approach for characterizing immunogenic responses toward a bispecific antibodySivan Cohen, Shan Chung, Christoph Spiess, et al.
Mabs|July 6, 2021
Stability of a high-concentration monoclonal antibody solution produced by liquid-liquid phase separationJack E Bramham, Stephanie A Davies, Adrian Podmore, et al.
Mabs|May 11, 2022
Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variantsTatsuhiko Ozawa, Hideki Tani, Yuki Anraku, et al.
Mabs|May 11, 2022
The human antibody sequence space and structural design of the V, J regions, and CDRH3 with RosettaSamuel Schmitz, Emily A Schmitz, James E Crowe, et al.
Pageof 180